Hakuei Yamashita
Research Subjects
Hakuei Yamashita has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hanako Furukori
Department of Psychiatry, Kuroishi-Akebono Hospital, Kuroishi, Japan
1 shared publication Hiroo Yoda
Department of Psychiatry, Moro Hospital, Saitama, Japan
1 shared publication- Ikuko Kishida
Department of Psychiatry, Fujisawa Hospital, Fujisawa, Japan
1 shared publication - Manabu Saito
Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan
1 shared publication Michiko Kuwabara
Department of Psychiatry, Moro Hospital, Saitama, Japan
1 shared publication- Mitsunori Hatakeyama
Department of Psychiatry, Higashidai Hospital, Odate, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 21
Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia
Lifestyle factors, such as an unbalanced diet and lack of physical activity, may affect the prevalence of metabolic syndrome (MetS) in schizophrenic patients. The aim of this study was to compare the MetS prevalence between inpatients and outpatients among schizophrenic population in Japan. We recruited inpatients (n = 759) and outpatients (n = 427) with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder from 7 psychiatric hospitals using a cross-sectional design. MetS prevalence was assessed using three different definitions, including the adapted National Cholesterol Education Program Adult Treatment Panel (ATP III-A). The overall MetS prevalences based on the ATP III-A definition were 15.8% in inpatients and 48.1% in outpatients. In a logistic regression model with age and body mass index as covariates, being a schizophrenic outpatient, compared to being a schizophrenic inpatient, was a significant independent factor (odds ratio = 3.66 for males, 2.48 for females) in the development of MetS under the ATP III-A definition. The difference in MetS prevalence between inpatients and outpatients was observed for all age groups in males and for females over 40 years of age. Outpatients with schizophrenia or schizoaffective disorder in Japan had a high prevalence of MetS compared to inpatients. MetS in schizophrenic outpatients should be carefully monitored to minimize the risks. A change of lifestyle might improve MetS in schizophrenic patients.
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 21
Open AccessComparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia
Lifestyle factors, such as an unbalanced diet and lack of physical activity, may affect the prevalence of metabolic syndrome (MetS) in schizophrenic patients. The aim of this study was to compare the MetS prevalence between inpatients and outpatients among schizophrenic population in Japan. We recruited inpatients (n = 759) and outpatients (n = 427) with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder from 7 psychiatric hospitals using a cross-sectional design. MetS prevalence was assessed using three different definitions, including the adapted National Cholesterol Education Program Adult Treatment Panel (ATP III-A). The overall MetS prevalences based on the ATP III-A definition were 15.8% in inpatients and 48.1% in outpatients. In a logistic regression model with age and body mass index as covariates, being a schizophrenic outpatient, compared to being a schizophrenic inpatient, was a significant independent factor (odds ratio = 3.66 for males, 2.48 for females) in the development of MetS under the ATP III-A definition. The difference in MetS prevalence between inpatients and outpatients was observed for all age groups in males and for females over 40 years of age. Outpatients with schizophrenia or schizoaffective disorder in Japan had a high prevalence of MetS compared to inpatients. MetS in schizophrenic outpatients should be carefully monitored to minimize the risks. A change of lifestyle might improve MetS in schizophrenic patients.
- 4 September 2010
- Published by Springer Nature in Psychopharmacology
- Vol. 213 (1) , 1-9
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine
Rationale Olanzapine (OLZ) is known to cause weight gain and metabolic disturbances, which may have serious implications with respect to medical comorbidities such as metabolic syndrome and insulin resistance. Objectives The aim of this study was to evaluate the effects of two angiotensin II type 1 receptor blockers (ARBs) which are widely used as antihypertensive agents, valsartan (VAL) and telmisartan (TEL), on insulin resistance in patients with schizophrenia treated with OLZ. Methods Thirty inpatients with schizophrenia with OLZ monotherapy over 8 weeks participated in this study. To assess insulin resistance, the homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (PG) levels and immunoreactive insulin (IRI) levels were measured \( [{\hbox{HOMA}} - {\hbox{IR}} = {\hbox{fasting\ PG\ level}}\ \left( {{\hbox{mmol}}/{\hbox{L}}} \right)\ \!\!\!\times {\hbox{fasting\ IRI\ {\hbox{level}}}}\ \left( {\mu {\hbox{U}}/{\hbox{ml}}} \right)/22.5] \). VAL add-on treatment was performed in insulin-resistant patients (HOMA-IR > 1.6) for 12 weeks. After a 12-week VAL washout period, TEL add-on treatment was carried out for 12 weeks. The effects of ARBs on insulin resistance and other metabolic variables were assessed. Results In all 30 patients, both body mass index and abdominal circumference were strongly correlated with HOMA-IR. Twelve patients showed high HOMA-IR and were deemed to be insulin resistant. Add-on therapy of VAL and TEL resulted in a significant decrease in fasting IRI levels and HOMA-IR. No differences in any effects were observed between VAL and TEL. No adverse effects of either ARBs were observed in this study. Conclusions ARBs for patients treated with OLZ improved insulin sensitivity and attenuated insulin resistance.- 4 September 2010
- Published by Springer Nature in Psychopharmacology
- Vol. 213 (1) , 1-9
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine
Rationale Olanzapine (OLZ) is known to cause weight gain and metabolic disturbances, which may have serious implications with respect to medical comorbidities such as metabolic syndrome and insulin resistance. Objectives The aim of this study was to evaluate the effects of two angiotensin II type 1 receptor blockers (ARBs) which are widely used as antihypertensive agents, valsartan (VAL) and telmisartan (TEL), on insulin resistance in patients with schizophrenia treated with OLZ. Methods Thirty inpatients with schizophrenia with OLZ monotherapy over 8 weeks participated in this study. To assess insulin resistance, the homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (PG) levels and immunoreactive insulin (IRI) levels were measured \( [{\hbox{HOMA}} - {\hbox{IR}} = {\hbox{fasting\ PG\ level}}\ \left( {{\hbox{mmol}}/{\hbox{L}}} \right)\ \!\!\!\times {\hbox{fasting\ IRI\ {\hbox{level}}}}\ \left( {\mu {\hbox{U}}/{\hbox{ml}}} \right)/22.5] \). VAL add-on treatment was performed in insulin-resistant patients (HOMA-IR > 1.6) for 12 weeks. After a 12-week VAL washout period, TEL add-on treatment was carried out for 12 weeks. The effects of ARBs on insulin resistance and other metabolic variables were assessed. Results In all 30 patients, both body mass index and abdominal circumference were strongly correlated with HOMA-IR. Twelve patients showed high HOMA-IR and were deemed to be insulin resistant. Add-on therapy of VAL and TEL resulted in a significant decrease in fasting IRI levels and HOMA-IR. No differences in any effects were observed between VAL and TEL. No adverse effects of either ARBs were observed in this study. Conclusions ARBs for patients treated with OLZ improved insulin sensitivity and attenuated insulin resistance.